英国生物银行:加强对新冠肺炎流行病学和长期影响的评估

Cambridge prisms, Precision medicine Pub Date : 2023-08-29 eCollection Date: 2023-01-01 DOI:10.1017/pcm.2023.18
Qi Feng, Ben Lacey, Jelena Bešević, Wemimo Omiyale, Megan Conroy, Fenella Starkey, Catherine Calvin, Howard Callen, Laura Bramley, Samantha Welsh, Allen Young, Mark Effingham, Alan Young, Rory Collins, Jo Holliday, Naomi Allen
{"title":"英国生物银行:加强对新冠肺炎流行病学和长期影响的评估","authors":"Qi Feng, Ben Lacey, Jelena Bešević, Wemimo Omiyale, Megan Conroy, Fenella Starkey, Catherine Calvin, Howard Callen, Laura Bramley, Samantha Welsh, Allen Young, Mark Effingham, Alan Young, Rory Collins, Jo Holliday, Naomi Allen","doi":"10.1017/pcm.2023.18","DOIUrl":null,"url":null,"abstract":"<p><p>UK Biobank is an intensively characterised prospective cohort of 500,000 adults aged 40-69 years when recruited between 2006 and 2010. The study was established to enable researchers worldwide to undertake health-related research in the public interest. The existence of such a large, detailed prospective cohort with a high degree of participant engagement enabled its rapid repurposing for coronavirus disease-2019 (COVID-19) research. In response to the pandemic, the frequency of updates on hospitalisations and deaths among participants was immediately increased, and new data linkages were established to national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and primary care health records to facilitate research into the determinants of severe COVID-19. UK Biobank also instigated several sub-studies on COVID-19. In 2020, monthly blood samples were collected from approximately 20,000 individuals to investigate the distribution and determinants of SARS-CoV-2 infection, and to assess the persistence of antibodies following infection with another blood sample collected after 12 months. UK Biobank also performed repeat imaging of approximately 2,000 participants (half of whom had evidence of previous SARS-CoV-2 infection and half did not) to investigate the impact of the virus on changes in measures of internal organ structure and function. In addition, approximately 200,000 UK Biobank participants took part in a self-test SARS-CoV-2 antibody sub-study (between February and November 2021) to collect objective data on previous SARS-CoV-2 infection. These studies are enabling unique research into the genetic, lifestyle and environmental determinants of SARS-CoV-2 infection and severe COVID-19, as well as their long-term health effects. UK Biobank's contribution to the national and international response to the pandemic represents a case study for its broader value, now and in the future, to precision medicine research.</p>","PeriodicalId":72491,"journal":{"name":"Cambridge prisms, Precision medicine","volume":" ","pages":"e30"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953745/pdf/","citationCount":"0","resultStr":"{\"title\":\"UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019.\",\"authors\":\"Qi Feng, Ben Lacey, Jelena Bešević, Wemimo Omiyale, Megan Conroy, Fenella Starkey, Catherine Calvin, Howard Callen, Laura Bramley, Samantha Welsh, Allen Young, Mark Effingham, Alan Young, Rory Collins, Jo Holliday, Naomi Allen\",\"doi\":\"10.1017/pcm.2023.18\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>UK Biobank is an intensively characterised prospective cohort of 500,000 adults aged 40-69 years when recruited between 2006 and 2010. The study was established to enable researchers worldwide to undertake health-related research in the public interest. The existence of such a large, detailed prospective cohort with a high degree of participant engagement enabled its rapid repurposing for coronavirus disease-2019 (COVID-19) research. In response to the pandemic, the frequency of updates on hospitalisations and deaths among participants was immediately increased, and new data linkages were established to national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and primary care health records to facilitate research into the determinants of severe COVID-19. UK Biobank also instigated several sub-studies on COVID-19. In 2020, monthly blood samples were collected from approximately 20,000 individuals to investigate the distribution and determinants of SARS-CoV-2 infection, and to assess the persistence of antibodies following infection with another blood sample collected after 12 months. UK Biobank also performed repeat imaging of approximately 2,000 participants (half of whom had evidence of previous SARS-CoV-2 infection and half did not) to investigate the impact of the virus on changes in measures of internal organ structure and function. In addition, approximately 200,000 UK Biobank participants took part in a self-test SARS-CoV-2 antibody sub-study (between February and November 2021) to collect objective data on previous SARS-CoV-2 infection. These studies are enabling unique research into the genetic, lifestyle and environmental determinants of SARS-CoV-2 infection and severe COVID-19, as well as their long-term health effects. UK Biobank's contribution to the national and international response to the pandemic represents a case study for its broader value, now and in the future, to precision medicine research.</p>\",\"PeriodicalId\":72491,\"journal\":{\"name\":\"Cambridge prisms, Precision medicine\",\"volume\":\" \",\"pages\":\"e30\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10953745/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cambridge prisms, Precision medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1017/pcm.2023.18\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cambridge prisms, Precision medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/pcm.2023.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

英国生物样本库是一个集中描述特征的前瞻性队列,在 2006 年至 2010 年期间招募了 50 万名年龄在 40-69 岁之间的成年人。建立这项研究的目的是为了让全世界的研究人员能够开展与公众利益相关的健康研究。有了这样一个庞大、详细、参与者参与度高的前瞻性队列,冠状病毒病-2019(COVID-19)的研究就可以迅速重新使用。为应对大流行,英国生物库立即增加了对参与者住院和死亡情况的更新频率,并与国家严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)检测和初级保健健康记录建立了新的数据链接,以促进对严重 COVID-19 决定因素的研究。英国生物库还启动了几项关于 COVID-19 的子研究。2020 年,每月收集约 20,000 人的血液样本,调查 SARS-CoV-2 感染的分布和决定因素,并在 12 个月后收集另一份血液样本,评估感染后抗体的持续性。英国生物库还对大约 2000 名参与者(其中一半有以前感染过 SARS-CoV-2 的证据,另一半没有)进行了重复成像,以调查病毒对内部器官结构和功能变化的影响。此外,约 200,000 名英国生物库参与者参加了一项自我检测 SARS-CoV-2 抗体的子研究(2021 年 2 月至 11 月),以收集有关以前感染过 SARS-CoV-2 的客观数据。这些研究有助于对 SARS-CoV-2 感染和严重 COVID-19 的遗传、生活方式和环境决定因素及其对健康的长期影响进行独特的研究。英国生物库为国家和国际应对大流行病所做的贡献是一个案例研究,它体现了英国生物库现在和将来对精准医学研究的更广泛价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019.

UK Biobank is an intensively characterised prospective cohort of 500,000 adults aged 40-69 years when recruited between 2006 and 2010. The study was established to enable researchers worldwide to undertake health-related research in the public interest. The existence of such a large, detailed prospective cohort with a high degree of participant engagement enabled its rapid repurposing for coronavirus disease-2019 (COVID-19) research. In response to the pandemic, the frequency of updates on hospitalisations and deaths among participants was immediately increased, and new data linkages were established to national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing and primary care health records to facilitate research into the determinants of severe COVID-19. UK Biobank also instigated several sub-studies on COVID-19. In 2020, monthly blood samples were collected from approximately 20,000 individuals to investigate the distribution and determinants of SARS-CoV-2 infection, and to assess the persistence of antibodies following infection with another blood sample collected after 12 months. UK Biobank also performed repeat imaging of approximately 2,000 participants (half of whom had evidence of previous SARS-CoV-2 infection and half did not) to investigate the impact of the virus on changes in measures of internal organ structure and function. In addition, approximately 200,000 UK Biobank participants took part in a self-test SARS-CoV-2 antibody sub-study (between February and November 2021) to collect objective data on previous SARS-CoV-2 infection. These studies are enabling unique research into the genetic, lifestyle and environmental determinants of SARS-CoV-2 infection and severe COVID-19, as well as their long-term health effects. UK Biobank's contribution to the national and international response to the pandemic represents a case study for its broader value, now and in the future, to precision medicine research.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信